XAGE - Carmell Corp
0.12
0.002 1.917%
Share volume: 226,595
Last Updated: 04-07-2025
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies:
-0.01%
PREVIOUS CLOSE
CHG
CHG%
$0.12
0.00
0.02%
Fundamental analysis
15%
Profitability
0%
Dept financing
25%
Liquidity
8%
Performance
30%
Performance
5 Days
-11.37%
1 Month
-51.50%
3 Months
-71.44%
6 Months
-64.39%
1 Year
-95.55%
2 Year
-98.82%
Key data
Stock price
$0.12
DAY RANGE
$0.10 - $0.12
52 WEEK RANGE
$0.10 - $2.93
52 WEEK CHANGE
-$95.14
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
Company detail
CEO: Rajiv Sarman Shukla
Region: US
Website: www.carmellrx.com
Employees: 14
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing
Region: US
Website: www.carmellrx.com
Employees: 14
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Recent news
